CXCL8 and cystic fibrosis: TMA, formerly known as a photoactive agent for the treatment of psoriasis by PUVA, is equipped with three types of activity useful for CF therapy: (1) inhibition of P. aeruginosa-dependent IL-8 transcription in different CF-derived bronchial epithelial cells (anti-inflammatory effect); (2) potentiation of CFTR-mediated chloride transport (CFTR potentiator); and (3) rescue of F508del CFTR (CFTR corrector) [5,6].